Black Swan Analysis
Welcome to all One Nucleus Members.
This page contains contact and information on the Black Swan Analysis Support Supply Agreement for Business Analysis and Marketing Support Services.
Click on the logo above for further information on what Black Swan Analysis can offer members.
Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we've seen what works and what doesn't and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today's complex healthcare marketplace.
The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.
Your Key Contacts
Pricing
Black Swan Analysis is well positioned to help any organisation in the healthcare industry analyse and determine the potential value of their assets. Whether it is a product with clinical data, or merely a fledgling concept, Black Swan can translate this information into a suitable format for both internal analysis and presentation to investors. Black Swan Analysis provides a range of asset valuation services in the Healthcare space from a summary report of the opportunity to a detail business case. A 20% discount will be applied to all One Nucleus members requiring this service.
For equity investors, Bio-tech companies and healthcare industry professionals, our Epiomic™ databases (www.epiomic.com) provides a reliable and evidence-based source of patient populations that goes beyond the basic prevalence rates to include essential conditions and patient attributes for each disease.
This data is essential for an investor or development team to understanding the potential patient population where their novel healthcare innovation fits in. This data has a use in due diligence exercises, fund raising, or to accurately size a clinical trial patient population with a specific condition.
The data is available across a wide range of disease types including diabetes, cardiovascular, cancer, ophthalmic and infectious diseases. The information can be provided on either an ad-hoc basis or through our subscription service on the web.
A discount of 20% on all standard pricing will be applied to all One Nucleus members purchasing the Epiomic database on an ad-hoc or subscription basis.
Please contact Black Swan Analysis for a list of options available.